Negev Capital
Tel Aviv · Seed
Find your way into Negev Capital
What they invest in
from 3 of 3 portfolio companiesBiotech ×3AI & Machine Learning ×2Digital Health ×2Healthtech ×2Medical Devices ×1Mental Health ×1
HQs:United States×2
Investments · 3 tracked
founders shown can be your intro pathBy year:2022 · 22021 · 13 dated
Delix Therapeutics develops third-generation, non-hallucinogenic neuroplastogens for people with neurological conditions, using a discovery platform to identify novel compounds.
BiotechDigital HealthMedical Devices
Co-investorsArtis VenturesCasa Verde CapitalNoeticOMX VenturesPsyMed VenturesRA Capital+6 more
Gilgamesh Pharmaceutical develops novel chemical entities for psychiatric disorders using medicinal chemistry and AI-powered translational platforms to design rapid-acting therapies targeting neurobiological mechanisms rather than symptom management.
AI & Machine LearningBiotechDigital HealthHealthtechNew York City, US
Jonathan Sporn(Founder)inAndrew Kruegel(Founder)inDalibor Sames(Founder)inJONATHAN SPORN(Founder)inAndrew Kruegel, Ph.D.(Executive Officer)Jonathan Sporn, M.D.(President and Chief Executive Officer)in
Co-investorsAera VCFrontera Technology VenturesFrontier Path VCJames Beshara FundJLSMagnetic Ventures+9 more
Mindstate Design Labs is a clinical-stage drug development company that uses AI to map the biological basis of emotion and cognition, synthesizing psychedelic phenomenology and biochemical data to design pharmaceutical compounds that induce specific therapeutic emotional and cognitive states for mental health treatment.
AI & Machine LearningBiotechHealthtechMental HealthSan Francisco, US
Dillan DiNardo(Founder/CEO)inTom Ray(Founder)in
BoardRand Hindi(Director)in
Co-investorsImmeasurableMetaplanetPsyMed VenturesY CombinatorDay One VenturesInitialized Capital+2 more
Portfolio news
latest coverage across their companies
Gilgamesh Pharmaceuticals · wmbdradio.com · Jul 16, 2026
Delix · ucdavis.edu · Sep 10, 2025
Frequently asked questions
- What stage does Negev Capital invest at?
- Negev Capital invests at the Seed stage.
- Where is Negev Capital located?
- Negev Capital is headquartered in Tel Aviv, IL.
Images
Co-investors · 5
PsyMed Ventures is an early-stage venture firm investing in neuroscience and frontier technologies aimed at improving brain and mental health.
RA Capital is a multi-stage investment firm focused on healthcare, life sciences, and planetary health, investing across public and private markets and creating new companies through its Raven incubation platform.
Artis Ventures is a venture capital firm focused on supporting founders reimagining the systems that sustain life, spanning from cellular biology to broader societal impact.
Firms observed investing alongside Negev Capital, from public investor directories. Shared companies are the overlap with Negev Capital's recorded portfolio.
Similar investors
4DI Ventures was co-founded by repeat tech operator and ESET Southern Africa founder Justin Stanford, giving it unusually deep cybersecurity and software operating experience rather than a purely financial background, and originated from Stanford's own angel-investing experiments that directly led to both the firm's creation and the launch of the Silicon Cape Initiative. The firm explicitly describes its style as "nurture capital" with intensive, hands-on engagement, and Stanford is vocal about avoiding the "unicorn at all costs" mentality in African tech, instead emphasizing sustainable market readiness and fundamentals in a more conservative, durability-focused investment approach.
83North is a global venture capital firm that invests in and helps entrepreneurs build large, category-defining companies, backing startups across multiple stages and sectors.
8VC is a venture capital firm investing across logistics, life sciences, healthcare, IT infrastructure, and government/defense, guided by its Smart Enterprise thesis focused on data integration and platform network effects.
ACT Venture Capital is an independent Irish venture capital firm that invests €1 million to €15 million in growth-stage private companies, with capacity for larger commitments through syndicated rounds.